Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
In the LEADER trial, over 9,340 patients with type 2 diabetes and high cardiovascular disease risk underwent randomization to liraglutide or placebo and were followed for a median of 3.8 years resulting in a 13% risk reduction in a combined endpoint of death from cardiovascular cause, nonfatal myocardial infarction, or nonfatal stroke [46]
Knowing this connection helps you better prepare for and manage this side effect during your treatment journey
& Lalonde, S
When your skin is stretched by excess weight, it can be difficult to feel comfortable in your clothing, even after you have shed the pounds
A consensus on diagnosis and management with countermeasures is detailed
What if I dont like the idea of injections
US$ 26.55
US$ 28.77
US$ 27.93
